

From: [REDACTED]@mscbs.es
To: EU NITAG COLLABORATION
Cc: [REDACTED]@mscbs.es; [REDACTED]@mscbs.es
Subject: RE: Request for INFORMATION - ongoing heterologous prime/boost COVID-19 vaccine trials
Date: 25 May 2021 18:30:59
Attachments: [image001.gif](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[Supplementary appendix_v5_only_protocol SAP.PDF](#)

EXTERNAL EMAIL - Do not click on any links, open attachments or reply, unless you recognise the sender's email address ([REDACTED]@mscbs.es) and believe the content is safe.

Dear colleagues,

Please find the responses below in red and the protocol of the study attached.

- Type of combination studied (e.g. vaccines studied and sequence): Administration of Comirnaty in subjects previously vaccinated with one dose of Vaxzevria at least 8 weeks before
- Planned trial period: one year (including laboratory research with the samples obtained)
- Trial participants: 600 subjects younger than 60 years, previously vaccinated with one dose of Vaxzevria
- Primary and secondary study endpoints: 1) analyze the increment of antibodies against SARS-CoV-2 14 days after the administration of one dose of Comirnaty; 2) analyze the reactogenicity of the heterologous scheme

If at all feasible, please kindly share any relevant information by Tuesday 25 May end-of-day, in order to be incorporated into the presentation.

<https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/PresentacionEnsayoCombivacs.aspx>

<https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/Presentaci%c3%b3n-resultados-preliminares-CombivacS.aspx>

kind regards,

[REDACTED]
[REDACTED]
DIRECTORATE GENERAL OF PUBLIC HEALTH
Ministry of Health
Paseo del Prado, 18-20. Office [REDACTED]
28071 Madrid. Spain.

Telephone: (+34) [REDACTED]
Fax: (+34) [REDACTED]
Email: [REDACTED]@mscbs.es

De: EU NITAG COLLABORATION [mailto:EU.NITAG.COLLABORATION@ecdc.europa.eu]

Enviado el: lunes, 24 de mayo de 2021 17:08

Para: [REDACTED]

[REDACTED]@mscbs.es; [REDACTED]@mscbs.es;

[REDACTED]

CC: EU NITAG COLLABORATION; [REDACTED]

Asunto: Request for INFORMATION – ongoing heterologous prime/boost COVID-19 vaccine trials

Dear Colleagues -

On Wednesday 26 May 2021, our team at ECDC is requested to provide an update on “Heterologous combinations of vaccine doses for COVID-19 (so-called “mix and match” studies) as part of a Health Security Committee (HSC) meeting. The HSC focal point(s) in your country may have informed you.

While preparing for this, we understand that we are lacking a comprehensive overview of ongoing or planned “mix and match studies”.

Would you kindly take a few minutes to indicate of ongoing and or planned studies in your country that you may be aware of and that are investigating the safety, immunogenicity and/or efficacy of COVID-19 vaccine in a mixed schedule?

Information that would be relevant to receive include:

- Type of combination studied (e.g. vaccines studied and sequence)
- Planned trial period
- Trial participants
- Primary and secondary study endpoints

If at all feasible, please kindly share any relevant information by Tuesday 25 May end-of-day, in order to be incorporated into the presentation.

We would kindly acknowledge your contribution.

Best regards,

[REDACTED]

ECDC VPI Team

ECDC Logo



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01

www.ecdc.europa.eu

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous

transmittal.

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.